Anti-GP171/ GPR171/ H963 monoclonal antibody

Anti-GP171/ GPR171/ H963 antibody for FACS & in-vivo assay

Target products collectionGo to GPR171/GPR171 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0522-Ab-1/ GM-Tg-hg-MP0522-Ab-2Anti-Human GPR171 monoclonal antibodyHuman
GM-Tg-rg-MP0522-Ab-1/ GM-Tg-rg-MP0522-Ab-2Anti-Rat GPR171 monoclonal antibodyRat
GM-Tg-mg-MP0522-Ab-1/ GM-Tg-mg-MP0522-Ab-2Anti-Mouse GPR171 monoclonal antibodyMouse
GM-Tg-cynog-MP0522-Ab-1/ GM-Tg-cynog-MP0522-Ab-2Anti-Cynomolgus/ Rhesus macaque GPR171 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0522-Ab-1/ GM-Tg-felg-MP0522-Ab-2Anti-Feline GPR171 monoclonal antibodyFeline
GM-Tg-cang-MP0522-Ab-1/ GM-Tg-cang-MP0522-Ab-2Anti-Canine GPR171 monoclonal antibodyCanine
GM-Tg-bovg-MP0522-Ab-1/ GM-Tg-bovg-MP0522-Ab-2Anti-Bovine GPR171 monoclonal antibodyBovine
GM-Tg-equg-MP0522-Ab-1/ GM-Tg-equg-MP0522-Ab-2Anti-Equine GPR171 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0522-Ab-1/ GM-Tg-hg-MP0522-Ab-2; GM-Tg-rg-MP0522-Ab-1/ GM-Tg-rg-MP0522-Ab-2;
GM-Tg-mg-MP0522-Ab-1/ GM-Tg-mg-MP0522-Ab-2; GM-Tg-cynog-MP0522-Ab-1/ GM-Tg-cynog-MP0522-Ab-2;
GM-Tg-felg-MP0522-Ab-1/ GM-Tg-felg-MP0522-Ab-2; GM-Tg-cang-MP0522-Ab-1/ GM-Tg-cang-MP0522-Ab-2;
GM-Tg-bovg-MP0522-Ab-1/ GM-Tg-bovg-MP0522-Ab-2; GM-Tg-equg-MP0522-Ab-1/ GM-Tg-equg-MP0522-Ab-2
Products NameAnti-GPR171 monoclonal antibody
Formatmab
Target NameGPR171
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GPR171 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species GP171/ GPR171/ H963 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0522
    Target NameGPR171
    Gene ID29909,229323,688737,709960,485716,109491438,767929,100050352
    Gene Symbol and SynonymsA630006E05,F730001G15Rik,GPR171,H963
    Uniprot AccessionO14626,D4A4Q2,Q3ZBK9
    Uniprot Entry NameGP171_HUMAN,D4A4Q2_RAT,GP171_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000174946
    Target ClassificationGPCR

    The target: GPR171, gene name: GPR171, also named as H963. Predicted to enable G protein-coupled purinergic nucleotide receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Predicted to act upstream of or within negative regulation of myeloid cell differentiation. Predicted to be located in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.